AXL was upregulated in 76% of patients with colorectal cancer and strongly correlated with a mesenchymal phenotype, whereas 37% of TGFBR2high and 65% of tumors TGFBR1high were attributed to the CMS4 subtype. The gene discussed is AXL; the disease is colorectal cancer.